Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 133

1.

Long-term changes in northern large-herbivore communities reveal differential rewilding rates in space and time.

Speed JDM, Austrheim G, Kolstad AL, Solberg EJ.

PLoS One. 2019 May 21;14(5):e0217166. doi: 10.1371/journal.pone.0217166. eCollection 2019.

2.

Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma.

Köksal H, Dillard P, Josefsson SE, Maggadottir SM, Pollmann S, Fåne A, Blaker YN, Beiske K, Huse K, Kolstad A, Holte H, Kvalheim G, Smeland EB, Myklebust JH, Inderberg EM, Wälchli S.

Blood Adv. 2019 Apr 23;3(8):1230-1243. doi: 10.1182/bloodadvances.2018029678.

3.

Effects of Caffeine on Exertion, Skill Performance and Physicality in Ice Hockey.

Madden RF, Erdman KA, Shearer J, Spriet LL, Ferber R, Kolstad AT, Bigg JL, Gamble ASD, Benson LC.

Int J Sports Physiol Perform. 2019 Apr 8:1-26. doi: 10.1123/ijspp.2019-0130. [Epub ahead of print]

PMID:
30958066
4.

TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma.

Josefsson SE, Beiske K, Blaker YN, Førsund MS, Holte H, Østenstad B, Kimby E, Köksal H, Wälchli S, Bai B, Smeland EB, Levy R, Kolstad A, Huse K, Myklebust JH.

Cancer Immunol Res. 2019 Mar;7(3):355-362. doi: 10.1158/2326-6066.CIR-18-0351. Epub 2019 Jan 18.

PMID:
30659053
5.

The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy.

Holte H, Beiske K, Boyle M, Trøen G, Blaker YN, Myklebust J, Kvaløy S, Rosenwald A, Lingjaerde OC, Rimsza LM, Smeland EB, Scott DW, Kolstad A.

Br J Haematol. 2018 Oct;183(2):225-234. doi: 10.1111/bjh.15518. Epub 2018 Aug 6.

PMID:
30080252
6.

Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma.

Eskelund CW, Albertsson-Lindblad A, Kolstad A, Laurell A, Räty R, Pedersen LB, Geisler CH, Jerkeman M, Grønbæk K.

Haematologica. 2018 Nov;103(11):e541-e543. doi: 10.3324/haematol.2018.194399. Epub 2018 May 24. No abstract available.

7.

Contrasting spatial, temporal and environmental patterns in observation and specimen based species occurrence data.

Speed JDM, Bendiksby M, Finstad AG, Hassel K, Kolstad AL, Prestø T.

PLoS One. 2018 Apr 26;13(4):e0196417. doi: 10.1371/journal.pone.0196417. eCollection 2018.

8.

Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients.

Stokke C, Blakkisrud J, Løndalen A, Dahle J, Martinsen ACT, Holte H, Kolstad A.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1233-1241. doi: 10.1007/s00259-018-3964-9. Epub 2018 Feb 22.

9.

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.

Jerkeman M, Eskelund CW, Hutchings M, Räty R, Wader KF, Laurell A, Toldbod H, Pedersen LB, Niemann CU, Dahl C, Kuitunen H, Geisler CH, Grønbæk K, Kolstad A.

Lancet Haematol. 2018 Mar;5(3):e109-e116. doi: 10.1016/S2352-3026(18)30018-8. Epub 2018 Jan 29.

PMID:
29396091
10.

T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.

Josefsson SE, Huse K, Kolstad A, Beiske K, Pende D, Steen CB, Inderberg EM, Lingjærde OC, Østenstad B, Smeland EB, Levy R, Irish JM, Myklebust JH.

Clin Cancer Res. 2018 Feb 15;24(4):870-881. doi: 10.1158/1078-0432.CCR-17-2337. Epub 2017 Dec 7.

11.

Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan.

Blakkisrud J, Holtedahl JE, Løndalen A, Dahle J, Bach-Gansmo T, Holte H, Nygaard S, Kolstad A, Stokke C.

J Nucl Med. 2018 Apr;59(4):704-710. doi: 10.2967/jnumed.117.195347. Epub 2017 Aug 28.

12.

TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.

Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, Montano-Almendras CP, Husby S, Freiburghaus C, Ek S, Pedersen A, Niemann C, Räty R, Brown P, Geisler CH, Andersen MK, Guldberg P, Jerkeman M, Grønbæk K.

Blood. 2017 Oct 26;130(17):1903-1910. doi: 10.1182/blood-2017-04-779736. Epub 2017 Aug 17.

13.

Long-term outcome of patients with solitary plasmacytoma treated with radiotherapy: A population-based, single-center study with median follow-up of 13.7 years.

Barzenje DA, Kolstad A, Ghanima W, Holte H.

Hematol Oncol. 2018 Feb;36(1):217-223. doi: 10.1002/hon.2415. Epub 2017 Apr 9.

PMID:
28393375
14.

What strategies can be used to effectively reduce the risk of concussion in sport? A systematic review.

Emery CA, Black AM, Kolstad A, Martinez G, Nettel-Aguirre A, Engebretsen L, Johnston K, Kissick J, Maddocks D, Tator C, Aubry M, Dvořák J, Nagahiro S, Schneider K.

Br J Sports Med. 2017 Jun;51(12):978-984. doi: 10.1136/bjsports-2016-097452. Epub 2017 Mar 2. Review.

PMID:
28254746
15.

Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.

Kolstad A, Pedersen LB, Eskelund CW, Husby S, Grønbæk K, Jerkeman M, Laurell A, Räty R, Elonen E, Andersen NS, Brown PD, Kimby E, Bentzen H, Sundström C, Ehinger M, Karjalainen-Lindsberg ML, Delabie J, Ralfkiær E, Fagerli UM, Nilsson-Ehle H, Lauritzsen GF, Kuittinen O, Niemann C, Geisler CH; Nordic Lymphoma Group.

Biol Blood Marrow Transplant. 2017 Mar;23(3):428-435. doi: 10.1016/j.bbmt.2016.12.634. Epub 2016 Dec 27.

16.

Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.

Myklebust JH, Brody J, Kohrt HE, Kolstad A, Czerwinski DK, Wälchli S, Green MR, Trøen G, Liestøl K, Beiske K, Houot R, Delabie J, Alizadeh AA, Irish JM, Levy R.

Blood. 2017 Feb 9;129(6):759-770. doi: 10.1182/blood-2016-05-718494. Epub 2016 Dec 23.

17.

Mass Cytometry of Follicular Lymphoma Tumors Reveals Intrinsic Heterogeneity in Proteins Including HLA-DR and a Deficit in Nonmalignant Plasmablast and Germinal Center B-Cell Populations.

Wogsland CE, Greenplate AR, Kolstad A, Myklebust JH, Irish JM, Huse K.

Cytometry B Clin Cytom. 2017 Jan;92(1):79-87. doi: 10.1002/cyto.b.21498.

18.

15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.

Eskelund CW, Kolstad A, Jerkeman M, Räty R, Laurell A, Eloranta S, Smedby KE, Husby S, Pedersen LB, Andersen NS, Eriksson M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Workman CT, Garde C, Elonen E, Brown P, Grønbaek K, Geisler CH.

Br J Haematol. 2016 Nov;175(3):410-418. doi: 10.1111/bjh.14241. Epub 2016 Jul 5.

PMID:
27378674
19.

Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate.

Blakkisrud J, Løndalen A, Dahle J, Turner S, Holte H, Kolstad A, Stokke C.

J Nucl Med. 2017 Jan;58(1):55-61. doi: 10.2967/jnumed.116.180471. Epub 2016 Sep 1.

20.

Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan.

Blakkisrud J, Løndalen A, Martinsen AC, Dahle J, Holtedahl JE, Bach-Gansmo T, Holte H, Kolstad A, Stokke C.

J Nucl Med. 2017 Jan;58(1):48-54. doi: 10.2967/jnumed.116.173922. Epub 2016 Aug 4.

21.

Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA.

Mensali N, Ying F, Sheng VO, Yang W, Walseng E, Kumari S, Fallang LE, Kolstad A, Uckert W, Malmberg KJ, Wälchli S, Olweus J.

Oncoimmunology. 2016 Feb 18;5(5):e1138199. doi: 10.1080/2162402X.2016.1138199. eCollection 2016 May.

22.

Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma.

Barzenje DA, Holte H, Fosså A, Ghanima W, Liestøl K, Delabie J, Kolstad A.

Leuk Lymphoma. 2017 Mar;58(3):623-632. doi: 10.1080/10428194.2016.1204653. Epub 2016 Jul 7.

PMID:
27389974
23.

Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma.

Albertsson-Lindblad A, Kolstad A, Laurell A, Räty R, Grønbæk K, Sundberg J, Pedersen LB, Ralfkiær E, Karjalainen-Lindsberg ML, Sundström C, Ehinger M, Geisler C, Jerkeman M.

Blood. 2016 Oct 6;128(14):1814-1820. doi: 10.1182/blood-2016-03-704023. Epub 2016 Jun 27.

24.

Myeloid cell leukaemia 1 has a vital role in retinoic acid-mediated protection of Toll-like receptor 9-stimulated B cells from spontaneous and DNA damage-induced apoptosis.

Holm KL, Indrevaer RL, Myklebust JH, Kolstad A, Moskaug JØ, Naderi EH, Blomhoff HK.

Immunology. 2016 Sep;149(1):62-73. doi: 10.1111/imm.12629. Epub 2016 Jul 25.

25.

A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma.

Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Kolstad A, Loge JH, Maisenhölder M, Østenstad B, Kvaløy S, Holte H.

Br J Haematol. 2016 May;173(3):432-43. doi: 10.1111/bjh.13965. Epub 2016 Feb 23.

PMID:
26914167
26.

Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials.

Hoster E, Geisler CH, Doorduijn J, van der Holt B, Walewski J, Bloehdorn J, Ribrag V, Salles G, Hallek M, Pott C, Szymczyk M, Kolstad A, Laurell A, Räty R, Jerkeman M, Van't Veer M, Kluin-Nelemans JC, Klapper W, Unterhalt M, Dreyling M, Hermine O.

Leukemia. 2016 Jun;30(6):1428-30. doi: 10.1038/leu.2015.322. Epub 2015 Nov 24. No abstract available.

PMID:
26598017
27.

Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years.

Barzenje DA, Cvancarova Småstuen M, Liestøl K, Fosså A, Delabie J, Kolstad A, Holte H.

PLoS One. 2015 Jul 6;10(7):e0131158. doi: 10.1371/journal.pone.0131158. eCollection 2015.

28.

"In situ" vaccination for systemic effects in follicular lymphoma.

Kolstad A, Olweus J.

Oncoimmunology. 2015 Mar 19;4(7):e1014773. eCollection 2015 Jul.

29.

Response to protocol review scenario: documentation needed.

Doss S, Kolstad A.

Lab Anim (NY). 2015 Apr;44(4):131. doi: 10.1038/laban.730. No abstract available.

PMID:
25793677
30.

miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator.

Husby S, Ralfkiaer U, Garde C, Zandi R, Ek S, Kolstad A, Jerkeman M, Laurell A, Räty R, Pedersen LB, Pedersen A, Ehinger M, Sundström C, Karjalainen-Lindsberg ML, Delabie J, Clasen-Linde E, Brown P, Cowland JB, Workman CT, Geisler CH, Grønbæk K.

Blood. 2015 Apr 23;125(17):2669-77. doi: 10.1182/blood-2014-06-584193. Epub 2015 Mar 3.

31.

Content of endothelial progenitor cells in autologous stem cell grafts predict survival after transplantation for multiple myeloma.

Blix ES, Kildal AB, Bertelsen E, Waage A, Myklebust JH, Kolstad A, Husebekk A.

Biol Blood Marrow Transplant. 2015 May;21(5):840-7. doi: 10.1016/j.bbmt.2014.12.027. Epub 2015 Feb 14.

32.

Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway.

Smeland KB, Kiserud CE, Lauritzsen GF, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Kolstad A, Loge JH, Maisenhölder M, Kvaløy S, Holte H.

Haematologica. 2015 Jun;100(6):e240-3. doi: 10.3324/haematol.2014.119214. Epub 2015 Feb 14. No abstract available.

33.

Computerized image analysis of the Ki-67 proliferation index in mantle cell lymphoma.

Blaker YN, Brodtkorb M, Maddison J, Hveem TS, Nesheim JA, Mohn HM, Kolstad A, Geisler CH, Liestøl K, Smeland EB, Holte H, Delabie J, Danielsen H.

Histopathology. 2015 Jul;67(1):62-9. doi: 10.1111/his.12624. Epub 2015 Feb 5.

PMID:
25431344
34.

Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma.

Kolstad A, Kumari S, Walczak M, Madsbu U, Hagtvedt T, Bogsrud TV, Kvalheim G, Holte H, Aurlien E, Delabie J, Tierens A, Olweus J.

Blood. 2015 Jan 1;125(1):82-9. doi: 10.1182/blood-2014-07-592162. Epub 2014 Oct 7.

35.

Mental health care in China: review on the delivery and policy issues in 1949–2009 and the outlook for the next decade.

Li K, Sun X, Zhang Y, Kolstad A.

Acta Neuropsychiatr. 2014 Jun;26(3):134-45. Review.

PMID:
25279417
36.

[Allogeneic stem-cell transplantation in adults 1985-2012: results and development].

Husøy MA, Brinch L, Tjønnfjord GE, Gedde-Dahl T Jr, Heldal D, Holme PA, Dybedal I, Kolstad A, Akkök ÇA, Rollag H, Gaustad P, Bergan S, Egeland T, Josefsen D, Kvalheim G, Fløisand Y.

Tidsskr Nor Laegeforen. 2014 Sep 2;134(16):1569-75. doi: 10.4045/tidsskr.13.1415. eCollection 2014 Sep 2. Norwegian.

37.

SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study.

Nordström L, Sernbo S, Eden P, Grønbaek K, Kolstad A, Räty R, Karjalainen ML, Geisler C, Ralfkiaer E, Sundström C, Laurell A, Delabie J, Ehinger M, Jerkeman M, Ek S.

Br J Haematol. 2014 Jul;166(1):98-108. doi: 10.1111/bjh.12854. Epub 2014 Mar 29.

38.

Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.

Kolstad A, Laurell A, Jerkeman M, Grønbæk K, Elonen E, Räty R, Pedersen LB, Loft A, Bogsrud TV, Kimby E, Hansen PB, Fagerli UM, Nilsson-Ehle H, Lauritzsen GF, Lehmann AK, Sundstrom C, Karjalainen-Lindsberg ML, Ralfkiaer E, Ehinger M, Delabie J, Bentzen H, Schildt J, Kostova-Aherdan K, Frederiksen H, Brown Pde N, Geisler CH; Nordic Lymphoma Group.

Blood. 2014 May 8;123(19):2953-9. doi: 10.1182/blood-2013-12-541953. Epub 2014 Mar 20.

39.

Collectivism, individualism, and pragmatism in China: implications for perceptions of mental health.

Kolstad A, Gjesvik N.

Transcult Psychiatry. 2014 Apr;51(2):264-85. doi: 10.1177/1363461514525220.

PMID:
24616231
40.

High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era.

Blaker YN, Eide MB, Liestøl K, Lauritzsen GF, Kolstad A, Fosså A, Smeland EB, Holte H.

Leuk Lymphoma. 2014 Oct;55(10):2319-27. doi: 10.3109/10428194.2013.871632. Epub 2014 Mar 19.

PMID:
24432894
41.

Multimodal treatment with ALL-like chemotherapy, Auto-SCT and radiotherapy for lymphoblastic lymphoma.

Bersvendsen H, Kolstad A, Blystad AK, Aurlien E, Fosså A, Kvaløy SO, Holte H, Lauritzsen GF.

Acta Oncol. 2014 May;53(5):680-7. doi: 10.3109/0284186X.2013.855816. Epub 2013 Nov 18.

PMID:
24237392
42.

High-dose therapy with autologous stem cell support for lymphoma--from experimental to standard treatment.

Smeland KB, Kiserud CE, Lauritzsen GF, Fosså A, Hammerstrøm J, Jetne V, Kolstad A, Kvalheim G, Loge JH, Løkeland T, Tangen JM, Holte H, Kvaløy S.

Tidsskr Nor Laegeforen. 2013 Sep 3;133(16):1735-9. doi: 10.4045/tidsskr.13.0319. English, Norwegian.

43.

High-dose therapy with autologous stem cell support for lymphoma in Norway 1987-2008.

Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Fluge Ø, Fosså A, Hammerstrøm J, Kolstad A, Loge JH, Maisenhølder M, Østenstad B, Kvaløy S, Holte H.

Tidsskr Nor Laegeforen. 2013 Sep 3;133(16):1704-9. doi: 10.4045/tidsskr.13.0243. English, Norwegian.

44.

High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial.

Laurell A, Kolstad A, Jerkeman M, Räty R, Geisler CH.

Leuk Lymphoma. 2014 May;55(5):1206-8. doi: 10.3109/10428194.2013.825906. Epub 2013 Aug 28. No abstract available.

PMID:
23876100
45.

High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells.

Myklebust JH, Irish JM, Brody J, Czerwinski DK, Houot R, Kohrt HE, Timmerman J, Said J, Green MR, Delabie J, Kolstad A, Alizadeh AA, Levy R.

Blood. 2013 Feb 21;121(8):1367-76. doi: 10.1182/blood-2012-04-421826. Epub 2013 Jan 7.

46.

Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma.

Dahle J, Repetto-Llamazares AH, Mollatt CS, Melhus KB, Bruland OS, Kolstad A, Larsen RH.

Anticancer Res. 2013 Jan;33(1):85-95.

PMID:
23267131
47.

Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study.

Holte H, Leppä S, Björkholm M, Fluge O, Jyrkkiö S, Delabie J, Sundström C, Karjalainen-Lindsberg ML, Erlanson M, Kolstad A, Fosså A, Ostenstad B, Löfvenberg E, Nordström M, Janes R, Pedersen LM, Anderson H, Jerkeman M, Eriksson M.

Ann Oncol. 2013 May;24(5):1385-92. doi: 10.1093/annonc/mds621. Epub 2012 Dec 17.

PMID:
23247661
48.

Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma.

Blix ES, Irish JM, Husebekk A, Delabie J, Forfang L, Tierens AM, Myklebust JH, Kolstad A.

BMC Cancer. 2012 Oct 16;12:478. doi: 10.1186/1471-2407-12-478.

49.

Effect of pain management on immunization efficacy in mice.

Kolstad AM, Rodriguiz RM, Kim CJ, Hale LP.

J Am Assoc Lab Anim Sci. 2012 Jul;51(4):448-57.

50.

Altered BCR and CD40 signalling are associated with clinical outcome in small lymphocytic lymphoma/chronic lymphocytic leukaemia and marginal zone lymphoma patients.

Blix ES, Irish JM, Husebekk A, Delabie J, Tierens AM, Myklebust JH, Kolstad A.

Br J Haematol. 2012 Dec;159(5):604-8. doi: 10.1111/bjh.12073. Epub 2012 Oct 9. No abstract available.

Supplemental Content

Loading ...
Support Center